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Abstract 
Graves' disease (GD) is a type of autoimmune thyroid disease characterized by the 
presence of thyrotropin-receptor stimulating autoantibodies, resulting in excessive 
secretion of thyroid hormone. The disease can be manifested in both adults and 
children. 
Like many other autoimmune diseases. Graves' disease is a multifactorial disease that 
develops as a result of complex interaction between genetic susceptibility and 
environmental factors. Evidence for genetic association includes the familial 
clustering of Graves, disease and a considerable high concordance rate in 
monozygotic twins. The human leukocyte antigen (HLA) genes, located on 
chromosome 6p21 of the major histocompatibility complex (MHC) region, became a 
candidate in genetic association studies with Graves' disease. The results have 
confirmed the importance of certain HLA alleles though some associations were 
relatively weak or even controversial among different race populations. 
Studies from different geographic regions north and south of the equator have shown 
a relatively similar incidence and prevalence of GD regardless of race and different 
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environmental exposure. This may suggest some underlying genetic factors, which 
may contribute to these "background" incidences of GD. 
More recently, many studies have been performed searching for other genetic 
susceptibility genes, which lie outside the HLA region. One of the promising targets 
is the Cytotoxic T Lymphocyte Associated Antigen 4 (CTLA-4) gene. 
The human CTLA-4 gene maps to chromosome 2q33. It encodes a T-cell surface 
molecule, which is co-expressed with CD28 on activated T cells, but not expressed on 
resting T cells. CD28 and CTLA-4 are related members of the immunoglobulin 
supergene family. They bind to the B7 family ligands on professional antigen 
presenting cells. It was evident that the CD28/B7 binding is crucial for full T cell 
activation, abrogation of this binding resulting in T cell anergy. The CTLA4/B7 
binding provides an inhibitory signal for T cell activation, thus providing a role for 
down-regulation of T cell activation and the induction of peripheral tolerance, which 
is important for the T cell homeostasis. 
Recently, an association between the CTLA-4 gene codon 17 A-G polymorphism and 
Graves' disease was found in Caucasians and Japanese by both case-control and 
linkage studies. A study of 94 adult Chinese patients with Graves, disease has also 
shown an increased frequency of the G allele in patients when compared to match 
controls. 
The main purpose of this project is to clarify the association of the CTLA-4 gene 
codon 17 A-G polymorphism in Hong Kong Chinese children with Graves' disease. 
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We would like to test the hypothesis that if the CTLA-4 gene G allele has a genuine 
association with Graves' disease regardless of different ethnic origins, our Hong Kong 
Chinese children with Graves' disease should also show this association. Moreover, 
this association may be stronger as the genetic contribution is less likely to be diluted 
by the effect of environmental factors when disease manifests in childhood. The 
findings will be very significant if a positive correlation was found across different 
populations. 
A total of 123 unrelated Chinese children with Graves' disease (104 girls and 19 boys) 
and 158 unrelated healthy children (79 girls and 79 boys) were recruited. Genomic 
DNA was extracted from peripheral venous blood. The A-G dimorphism was 
determined by polymerase chain reaction (PGR), restriction fragment length 
polymorphism (RFLP), single strand conformation polymorphism (SSCP)，and 
sequencing analysis as described. 
By using the PCR-RFLP and PCR-SSCP approach, the CTLA-4 gene codon 17 A-G 
polymorphism was unambiguously identified in 123 patients and 158 controls. The 
distribution of the CTLA-4 alleles in all studied groups was in Hardy-Weinberg 
equilibrium. 
Upon statistical analysis, our results show that the genotype frequencies between 
patients and controls differed significantly (x^  = 12.14，p = 0.0023), as did the 
distribution of allele frequencies (x^  = 5.21，p 二 0.022). The overall odds ratio for the 
G allele in association with Graves' disease was 1.54 (CI = 1.04-2.28). The presence 
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of at least one G allele (GG or AG) conferred an odds ratio of 6.8 = 10.7, 95% CI 










































(X2=5.21, P=0.022)；而基因型頻率（genotype frequency)則差異顯著（X2=12.14, 
p=0.0023)�G等位基因與Graves'病關連的整體發生比率（odds ratio)爲1.54 
(CI=1.04-2.28) °而存在最少一個G等位基因（GG或AG)與發展成Graves’病的 
發生比率爲 6.8 (义2=10.7，95% CI=2.0~36.1, p=0.022)� 
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1.1 An overview to the study of CTLA-4 gene in childhood Graves' 
disease 
1.1.1 Graves' disease (GD) — features, incidence, aetiology and pathogenesis 
1.1.1.1 GD features - from clinical to laboratory 
Graves' disease, also known as autoimmune hyperthyroidism, is an organ specific 
autoimmune disease. The main clinical features of GD are a diffuse goitre associated 
with the symptoms and signs of thyrotoxicosis and the typical Graves' 
ophthalmopathy. Most cases of childhood GD present at around puberty (Wong et al” 
2001). Laboratory diagnosis shows a raised free thyroxine [T4] or triiodothyronine 
[T3] levels, suppressed thyroid stimulating hormone [TSH] levels and diffuse 
increased uptake on thyroid scan. Thyroid specific circulating autoantibodies against 
thyroglobulin, thyroid peroxidase and thyrotropin-receptor can be detected in GD. 
Though the presence of thyroid peroxidase and thyroglobulin autoantibodies indicates 
the presence of thyroid autoimmunity, they can also be detected in normal subjects 
(Mariotti et al., 1992). The hallmark of GD is the presence of thyrotropin-receptor 
autoantibodies, which activates the thyrotropin-receptor resulting in excessive 
production and secretion of thyroxine by the thyroid gland. 
Laboratory research findings at both cellular and subcellular level also show several 
systemic or thyroid gland abnormalities. Activated T cells can be detected in 
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peripheral circulation (Jackson et al., 1984) and they were also found to infiltrate the 
thyroid gland. The thyroid infiltrated T cells are mainly of the CD4+ Th2 subtype 
(Roura-Mir et al., 1997). Furthermore, aberrant expression of MHC II molecules by 
thyroid follicular cells was also reported in GD (Bottazzo et al., 1983; Hanafusa et al., 
1983; Matsunaga et al., 1986). The existence of multiple thyroid specific antibodies, 
enhanced expression of MHC II molecules in the thyroid follicular cells that was 
normally seen in antigen presenting cells (APC) only and the aggregation and 
activation of T lymphocytes delineate the immimo-pathogenesis of GD. 
1.1.1.2 GD incidence - from adult to children 
Graves' disease (GD) is a common autoimmune disease affecting the thyroid gland 
resulting in excessive secretion of thyroid hormone. It is relatively more common in 
adults than children, and female is more vulnerable than male to develope GD. The 
annual incidence rates in adults have been reported to be between 15 to 50/100,000 
persons per year (Barker et al., 1984; Brownlie et al., 1990; Vanderpump et al., 1995) 
and female is about eight to ten fold more than male to have GD. Epidemiological 
data on childhood GD is very limited. The most comprehensive epidemiological 
study of childhood GD available in the literature for the Caucasians was carried out in 
Denmark (Lavard et al., 1994). Fifty-six children (48 girls and 8 boys) under 15 years 
of age were confirmed to have GD during the years 1982 to 1988. The overall 
incidence was 0.79/100,OOO/yr. In Hong Kong, the incidence of Chinese children 
under 15 years of age having GD is high, with an overall incidence about five times 
(3.8/100,000/yr) that reported in Danish children (Wong et al., 1995). Furthermore, 
the incidence of childhood GD in Hong Kong was shown to be increasing, and 
attaining eight fold (6.5/100,000,yr) that of Danish children during the period of 1994 
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to 1998 (Wong et al., 2001). Therefore, the case load in Hong Kong provides a good 
opportunity to study the genetics of childhood Graves，disease. 
1.1.1.3 GD aetiology - from environment to genes 
The aetiology of Graves, disease is multifactorial. The interplay between 
environmental determinants and genetic susceptibility predispose to the development 
of GD. Early literature suggested that environmental insult like smoking (Hagg et al., 
1987), stress (Hobbs et al., 1992), Yersinia Enterocolitica infection (Keddie et al., 
1977), dietary iodine supplement (Barker et al., 1984) and neck irraidiation (Hancock 
et al., 1991) has correlation with GD. However, some of these studies like stress are 
very difficult to prove and most patients with Yersinia Enterocolitica infection do not 
develop thyroid autoimmune disease (Lindholm et al, 1991). 
Familial clustering and twin studies of autoimmune thyroid disease (AITD) including 
GD have been found in the early 19^ Century (Bartels et al.，1941; Harvald et al., 
1956; Martin L., 1945). HLA antigens were then reported to be associated with GD 
(Bech et al., 1977). The HLA DR3 allele was subsequently shown to be associated 
with Caucasians in many studies (Farid et al., 1980; Stenszky et al., 1985; 
Kendalltaylor et al., 1988). However, the HLA association with GD varies between 
ethnic groups. In Hong Kong, race specific HLA-DQ alleles associated with GD have 
been reported in Chinese children (Wong et al., 1999). A twin's study in Denmark 
showed that the concordance (simultaneous occurrence) rate of GD in monozygotic 
(MZ) twins is 35% in contrast to 3% in dizygotic (DZ) twins (Brix et al., 2001) 
suggesting other environmental factors other than genetics in the pathogenesis of GD. 
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1.1.1.4 GD pathogenesis - from autoantigen to autoantibody 
Genetic susceptibility and environmental factors contribute to the development of a 
number of autoimmune diseases including GD. Hyperthyroidism in GD is the direct 
consequence of the binding of activating autoantibodies to the thyrotropin receptor 
(TSHR). It was found that the TSHR would physiologically undergo intramolecular 
cleavage into disulfide-linked subunits. Recent mice immunization study using 
adenovirus vectors expressing human TSHR showed that the free TSHR A subimit 
instead of the TSH holo-receptor is the primary immunogen of TSHR autoantibodies 
causing GD (Chen et al.，2003). 
Thyroid follicular cells aberrantly expressed MHC class II molecule (Bottazzo et al., 
1983) and have been shown to function as antigen presenting cells (Londei et al., 
1985; Mackenzie et al., 1987). In an animal model of GD, immune hyperthyroidism 
can be induced by immunization of mice with fibroblast transfected with both the 
human TSHR and MHC class II molecule, but not either alone, (Shimojo et al., 1996). 
The results suggested that the expression of MHC II molecules together with TSHR 
could result in the induction of functional TSHR autoantibodies. It was concluded 
that the acquisition of antigen-presenting capability on a target cell containing the 
TSHR could activate the T and B cells in mice and induce a disease with the major 
features of human GD (Shimojo et al., 1996). 
During Ag presentation, the engagement of MHC-peptide to the T cell receptor (TCR) 
together with costimulatory signals activates the T cell. The subsequent cytokine 
signalling results in clonal expansion of T cells and activation of B cells to proliferate 
and progeny to differentiate into memory and plasma cells secreting antibody. 
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Although the autoantigen TSHR and the MHC II inducible thyroid follicular cells 
may contribute to the development of GD, majority of T cells specific for self-antigen 
can be tolerated without inducing autoimmunity (Akkaraju et al., 1997). The balance 
of co-stimulatory signals is essential for maintaining immune homeostasis and 
regulation of T cell function (Chambers and Allison, 1999) 
1.1.2 CTLA-4 gene study in Graves' disease 
Many studies have confirmed the association of Graves' disease and the Human 
leukocyte antigen (HLA) genes, but the associations were relatively weak (Roman et 
al” 1992; Ratanachaiyavong and McGregor, 1994). Recently, many studies have 
been performed in search of other genetic components which may be responsible for 
the susceptibility or protection, which lie outside the HLA region (Tomer et aL, 1999; 
Siegmimd et al., 1998; Rau et al., 1997). 
CTLA-4 (cytotoxic T lymphocyte associated antigen-4) is a T cell surface molecule, 
which is coexpressed with CD28 on activated T cells. Recent evidence suggests that 
CTLA-4 also binds the B7 family of receptor and such interaction is important in 
regulating self-tolerance (Bluestone, 1997). The B7/CTLA-4 co-stimulatory pathway 
has been found to be important in the pathogenesis of a variety of autoimmune 
diseases such as Graves' disease, Hashimoto's thyroiditis, Addison's disease and 
diabetes mellitus (Reiser & Stadecker，1996). Recently，a microstatellite 
polymorphism in the 3' untranslated region of the CTLA-4 gene has been shown to be 
associated with Graves' disease in Caucasians (Yanagawa et al., 1995; Kotsa et al., 
1997). Subsequently the association between the CTLA-4 exon one A/G 
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polymorphism and Graves' disease were found in Caucasians and Japanese (Dormer 
et al., 1997a; Yanagawa et aL, 1997; Vaidya et al, 1999). A study of 94 adult 
Chinese patients with Graves' disease has also shown an increased frequency of G 
allele in patients when compared to matched controls (Nistico et al., 1996). However, 
a recently described C-T polymorphism in exon one of the CTLA-4 promoter region 
was not found to be associated with Graves' disease in either Chinese or Caucasian 
adults (Heward et al, 1998). 
1.1.3 Conclusion 
We have documented a very high incidence of childhood Graves' disease in Hong 
Kong Chinese and the incidence appeared to be increasing (Wong et al” 1995 & 
2001). Race-specific HLA-DQ alleles have also been found to confer susceptibility 
or protection for Graves' disease in Chinese children (Wong et al., 1999). Recent 
literatures have shown that the CTLA-4 costimulatory molecule is associated with 
adult GD among populations in the West and East. In order to substantiate the genetic 
association of CTLA-4 gene with childhood GD in Hong Kong Chinese, the CTLA-4 
gene A/G polymorphism is a potential candidate gene for further study. These studies 
may possibly reveal some of the reasons that may explain the high incidence of 
childhood Graves' disease in Chinese. 
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1.2 Objectives, hypothesis and planning of the study 
1.2.1 Objectives 
To identify and compare the genotype composition of A-G polymorphism at codon 17 
nucleotide position 49 of the CTLA-4 gene exon one between Hong Kong Chinese 
children with Graves' disease and in controls. 
1.2.2 Hypothesis 
If the CTLA-4 gene is important in the pathogenesis of Graves' disease as reported in 
the Caucasian and Japanese adult patients, we should be able to demonstrate the 
association of CTLA-4 gene polymorphism and childhood Graves' disease in Chinese. 
1.2.3 Planning 
Unrelated Chinese children with GD were recruited from the Paediatric Endocrine 
Clinic at the Prince of Wales Hospital, Shatin, Hong Kong. The age matched controls 
of unrelated healthy children without clinical evidence or family history of any 
autoimmune thyroid disorders were recruited as controls. Parental consent was 
obtained for each case. Peripheral blood was obtained for DNA extraction and thyroid 
antibody assays. For the current study, a sample size of 140 cases and 140 case 
controls would have a power of 80% in detecting a minimal odds ratio of 2.8 for the 
association of G allele and Graves' disease at a significance level of 0.05 (2 sides) 




2.1 The CD28 / CTLA-4: B7 co-stimulatory pathway and Graves’ 
disease 
2.1.1 Overview of co-stimulation and T cell activation 
In 1970，Bretscher and Cohn was the first to postulate the two-signal model of 
lymphocyte activation to explain the self and non-self discrimination (Bretscher and 
Cohn, 1970). This model proposed that T cells require two collaborative but distinct 
signals for full activation. Binding of the loaded MHC molecules on APC to the 
antigen specific T cell receptor (TCR) on T cells together with the MHC restricted 
CD4 or CDS co-receptors provides the first signal (signal 1). Then the engagement of 
T cell surface molecules with their specific ligands on APC provided the second 
costimulatory signal (signal 2). Signalling through the TCR alone without signal 2 
lead to a state of T cell unresponsiveness termed anergy. The anergic T cell fails to 
produce the autocrine growth factor mterleukin-2 (IL-2) upon stimulation, but the 
anergic state can be reversed by the addition of exogenous IL-2 (Mueller et al.，1989). 
The most potent co-stimulatory pathway is the CD28/CTLA-4: B7 pathway. The B7 
family molecules belong to the immunoglobulin (Ig) superfamily, and the main 
ligands for CD28 and CTLA-4 gene are the B7.1 (CD80) and the B7.2 (CD86) 
molecules. These proteins are constitutively expressed on dendritic cells (DC), but 
can be up regulated on monocytes, B cells and probably other APC. The CD28 and 
its homologue CTLA-4 molecule also belong to the Ig superfamily; they are the 
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ligands for the B7 family molecules. The CD28 receptor is constitutively expressed 
on T cells while the CTLA-4 gene is expressed on T cell surface after T cell activation. 
Engagement of B7 molecules on APC with CD28 on naive T cells provides a 
costimulatory singal to T cells (Greenfield et al, 1998; Chambers et al, 2001 and 
Salomon et al.，2001). Furthermore, there are a variety of co-stimulatory molecules 
which may provide positive or negative signals (Van Parijs and Abbas, 1998). Newly 
emerged members or functions of previously reported costimulatory molecules are 
constantly under review (Chen L.P., 2004; Khoury et al., 2004 and Greenwald et al., 
2005). 
2.1.2 Overview of the CD28 gene 
The CD28 membrane protein was originally identified on human T cells. Molecular 
cloning of the CD28 cDNA in 1987 reveal that CD28 encodes a highly glycosylated 
membrane protein with homology to the immunoglobulin superfamily (Aruffo and 
Seed, 1987). Subsequently the CD 28 and CTLA-4 gene maps to chromosome 2q33-
q34 by in situ hybridisation (Lafage-Pochitaloff et al., 1990). The immunoglobulin 
domain of CD28 contains a motif, MYPPPY, which is critical for B7.1 (CD80) and 
B7.2 (CD86) binding (Peach et al., 1994). CD28 is a single copy gene and is 
organized into 4 exons, each of which defines a functional domain of the predicted 
protein. Posttranslational processing appears to result in different CD28 isoforms 
(Lee et al., 1990). Three CD28 splice variants have been found in non-activated T 
cells, suggesting that resting T cells may constitutively express both membrane and 
soluble CD28, which can potentially regulate the T cell response at different levels 
(Magistrelli et al.，1999a). 
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The proliferation and activation of T cells by CD28 is mainly through IL-2. CD28 
enhances the IL-2 receptor expression as well as the IL-2 gene transcription rate 
(Martin et al., 1986 and Fraser et al., 1991). CD28 also enhances the sensitivity of T 
cell towards lower dose of antigen challenge (Harding et al., 1992). In addition, 
upregulation of anti-apoptotic factor BC1-XL was found during CD28 costimulation 
(Boise et al, 1995). In CD28 deficient mice, the proliferative response and IL-2 
production of the CD28 deficient T cells are impaired and the basal serum Ig levels 
and post infection Ig levels are low suggesting that T cells from these mice are unable 
to provide adequate B cell help (Green et al., 1994). Thus the main function of CD28 
in T cell activation are promoting the proliferation of activated T cells via the 
autocrine IL-2 and IL-2 receptor synthesis, enhance the sensitivity towards antigen 
challenge, prolong the survival of T cells and provide signals to help the production of 
Ig in B cell. 
2.1.3 Overview of the CTLA-4 gene 
The CTLA-4 gene was originally identified as the fourth cDNA during the search for 
genes that are specifically expressed in mouse cytotoxic T cells cDNA libraries, and 
hence the name ‘cytolytic T-lymphocyte-associated antigen' four, CTLA-4 (Brunet et 
al., 1987). CTLA-4 is a member of the Ig superfamily and maps to chromosome 2q33, 
in close proximity to CD28. The putative protein contains four exons, which encoded 
a leader sequence, an extracelluar V domain, a transmembrane domain and a 
intracellular cytoplasmic tail (Harper et al., 1991). The extracellular domain also 
contains the motif, MYPPPY, which is essential for B7 ligand binding. A revised 
sequence (Ling et al., 1999) of the mouse and human CTLA-4 genes showed a high 
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homology in both the coding and non-coding region suggest a conserved 
transcriptional control at this locus. 
The expression of CTLA-4 gene was not detected on resting T cell surface. Upon T 
cell activation，CTLA-4 transcription is rapidly induced but protein expression peaks 
at 24 to 48 hours later (Lindsten et al., 1993). While full length CTLA-4 (flCTLA-4) 
transcript was detected on activated T cells, an alternatively splice variant of CTLA-4 
gene was found to be expressed by non-activated human peripheral blood T cells and 
could be detected on 14 out of 64 healthy subjects (Magistrelli et aL, 1999b). This 
splice variant was termed soluble CTLA-4 (sCTLA-4) in which the extracellular B7 
binding domain was conserved and the transmembrane region was deleted. The 
splicing induces a frame shift to generate a chain of 22 extra amino acids, which 
replaced the original intracellular cytoplasmic tail. It was shown that the sCTLA-4 is 
down regulated by T cell activation. sCTLA-4 can also be detected in autoimmune 
thyroid disease (AITD). 11 out of 20 patients with AITD (8 of 17 with GD and 3 of 3 
with Hashimoto thyroiditis) and one out of 30 controls were detected as positive 
(Oaks and Hallett, 2000). Besides flCTLA-4 and sCTLA-4 in human, another splice 
variant called ligand independent CTLA-4 (liCTLA-4) was observed in the NOD 
mouse model of type 1 diabetes. The liCTLA-4 lacks the extracellular B7 binding 
domain while keeping the transmembrane region and cytoplasmic tail intact，can 
strongly inhibit T cell responses by binding and dephosphorylating the TCR(^  chain. 
Similar to sCTLA-4, liCTLA-4 is expressed in resting T cells and rapidly 
downregulated early during T cell activation (Vijayakrishnan et al.，2004). 
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The CTLA-4 gene harbours a list of polymorphic sites from single nucleotide 
polymorphism (SNP) to microsatellite dinucleotide repeats. The most common site of 
polymorphism for gene association study is the -318 C/T polymorphism of the 
promoter region (Deichmann et al., 1996), the 49 A/G polymorphism of exon 1 
(Harper et al., 1991) and the 3，untranslated region (AT)n dinucleotide repeats 
polymorphism (Polymeropoulos et al.，1991). CTLA-4 associated with many 
autoimmune disorders, including primary biliary cirrhosis (Agarwal et al., 2000)， 
multiple sclerosis (Harbo et al., 1999), coeliac disease (Djilali-Saiah et al., 1998) and 
rheumatoid arthritis (Seidl et al., 1998 and Vaidya et al., 2002). The most extensive 
CTLA-4 gene association study of the above polymorphic hotspots is the 
investigation in autoimmune endocrinopathies such as Graves' disease, autoimmune 
hypothyroidism, type 1 diabetes mellitus and autoimmune Addison's disease as 
reviewed (Vaidya and Pearce, 2004), 
CTLA-4 is a glycoprotein homodimer expressed on activated T cells and binds the 
same B7 ligands (B7.1 and B7.2) as CD28 with at least 10 fold greater affinity 
(Greene et al., 1996). CTLA-4 can downregulate T cell response by negative 
signalling in response to TCR activation via the intracellular cytoplasmic domain 
which bears a motif known as an ITIM (immunoreceptor tyrosine-based inhibitory 
motif), can recruit inhibitory phosphatases to dephosphorylate signal transduction 
molecules activated by tyrosine kinase (Lee et al., 1998). The findings of soluble 
CTLA-4 fragment in 50% of AITD patients (Oaks and Hallett, 2000) may signified 
the mechanism that sCTLA-4 may act as a barrier, or behave like an blocking 
antibody, hinder the contact between B7 molecules and membrane anchored CTLA-4, 
so that activated T cells cannot be appropriately down regulated. 
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2.1.4 Co-stimulation and Graves' disease 
The classical model of T cell activation involves antigen processing, antigen 
presentation by professional antigen presenting cells, engagement of the MHC-Ag to 
TCR together with costimulatory signals will turn on the IL-2 and IL-2 receptor 
synthesis and T cell activation commence. In GD, circulation of activated T 
lymphocytes was evident (Jackson et al., 1984). This implies that at least some 
though maybe not all of the steps involved in T cell activation process are ongoing. 
One of the features is the aberrant expression of MHC II molecules (Bottazzo et al., 
1983; Hanafiisa et al., 1983; Matsimaga et al., 1986) and CD40 antigen on thyroid 
follicular cells (TFC) (Metcalfe et al., 1998). The CD40/CD40L signalling mediates 
T cell maturation (Grewal et al., 1995 and Van Essen et al., 1995), enhances cytokine 
production (Heloisa Blotta et al., 1996), and induces expression of other costimulatory 
molecules on APC (Clark et al., 1996; Grewal et al., 1996 and Shinde et al., 1996). 
Although TFC cannot express the B7 molecules, it is possible to acquire in trans. 
Many of the previously recognized membrane anchored costimulatory molecules on 
APC and T cells can be soluble. This included CD80 (Tatari-Calderone et al., 2002), 
CD86 (Jeannin et al., 2000), CD28 (Magistrelli et al., 1999a) and CTLA-4 
(Magistrelli et al., 1999b). The dynamic balance of these soluble costimulatory 
molecules is necessary for the maintenance of immuno-homeostasis. 
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2.2 The study of CTLA-4 gene polymorphism in Graves’ disease 
In 1995, there is the report of the association of a (AT)n dinucleotide repeats 
microsatellite polymorphism in the 3' untranslated region (UTR) of the CTLA-4 gene 
with Graves' disease in Caucasians (Yanagawa et al., 1995). In this study, 133 cases 
and 85 controls were alleotyped for the fragment size of microsatellite. It was found 
that the 106 bp fragment was in association with GD. Statistical analysis review a 
odds ratio (OR) of 2.8 for the association of the 106 bp fragment and disease with a p 
value of 0.012. Subsequently another research group with smaller sample size pool 
(112GD + 91 controls) have successfully analysed 21 allelotypes and among all, the 
106 allele was significantly increased in GD patients (Kotsa et al” 1997). It was 
proposed that the 3’ UTR may be responsible for the stabilization of mRNA. Then 
the research focus was directed towards another single nucleotide polymorphism 
located on the leading peptide position, the CTLA-4 gene exon 1 A/G polymorphism. 
The association between the CTLA-4 exon one A/G polymorphism and Graves' 
disease were found in Caucasians (Dormer et al., 1997b and Vaidya et al” 1999). 
These two studies recruited more than 300 GD subjects and controls. The G allele 
and GG genotype were found to confer increased risk of developing Graves' disease. 
The Japanese group also attains similar results with 153 cases and 200 controls 
(Yanagawa et al., 1997). The "G" allele again was associated with GD. Another 
recent study of 94 adult Chinese patients with Graves' disease has also shown an 
increased frequency of G allele in patients when compared to match controls (Nistico 
et al” 1996). However, a recently described C-T polymorphism in the CTLA-4 
promoter region was not found to be associated with Graves' disease in either Chinese 
or Caucasian adults (Heward et al, 1998). There has not been any study of the 
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CTLA-4 gene in childhood Graves' disease. Therefore, it is important to study this 
gene in childhood Graves' disease if there are enough cases for study as childhood 




3 • 1 Recruitment of subj ects 
3.1.1 Recruitment of cases 
A total of 123 (104 girls and 19 boys) unrelated Chinese children with Graves' 
disease were recruited from the Paediatric Endocrine Clinic at the Prince of Wales 
Hospital, Shatin，Hong Kong. There were all less than 15 years of age at diagnosis. 
The diagnosis of Graves' disease were based on the clinical features including diffuse 
thyroid gland enlargement, raised free thyroxine [T4] or triiodothyronine [T3] levels, 
suppressed TSH levels, positive TSH receptor autoantibodies and the presence of anti-
microsomal or anti-thyroglobulin antibodies. Transient neonatal hyperthyroid 
subjected were excluded. 
3.1.2 Recruitment of controls 
For the normal control, a total of 158 (79 girls and 79 boys) unrelated healthy children 
less than 15 years of age without clinical evidence or family history of any 
autoimmune thyroid disorders were recruited. They were subjects who participated in 
a community screening study for thyroid diseases in children (Wong et al., 1998). All 
controls were negative for thyroid autoantibodies (Serodia-ATG/AMC, Fujirebio, 
Japan). 
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3.1.3 Ethical approval 
The Ethics Committee of the Chinese University of Hong Kong approved the study, 
and informed parental consent was obtained from all participants. 
3.2 Peripheral blood collection and genomic DNA preparation 
3.2.1 Peripheral blood collection 
A total volume of 2.5 ml peripheral blood was collected inside the 
VACUETTE®EDTA tubes (Greiner Bio-One, North America). 
3.2.2 White blood cell (WBC) harvesting 
The EDTA tubes were centrifuged at 2000x g for 10 mins at 4®C and the plasma was 
removed. RBC lysis solution (lOmM KHCO3, 155mM NH4CI, 0.1 mM EDTA, pH 8) 
was added to the packed cells in a ratio of 3:1 (v/v), and placed on ice for 10 mins 
until all the RBC were lysed. WBC was then harvested by a further centrifligation of 
2000xgforl0minsat4®C. 
3.2.3 WBC digestion 
, The harvested WBC pellet was resuspended in one ml TE buffer (lOmM TRIS, ImM 
EDTA, pH 8), with the addition of 100 ul 20% sodium dodecyl sulphate (SDS) and 
100 ul of Proteinase K (lOmg/ml). The mixture was subjected to 37®C overnight 
digestion in a waterbath. 
3.2.4 DNA extraction 
The overnight digested WBC lysate was added with an equal volume of TRIS (IM， 
pH 8) saturated, TE (lOmM TRIS, ImM EDTA, pH 8) buffered phenol with 
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intermittent mixing for one min. Then the mixture was centrifliged for five mins at 
2000x g，4°C. The upper aqueous phase was retained. Then the extraction procedure 
was repeated with phenol/chloroform/isoamyl alcohol (25:24:1) and finally with 
chloroform. 
The final aqueous solution was mix with one-tenth volume of sodium acetate (3M, pH 
5.2). Then a two volume of ice-cold absolute ethanol was added. High molecular 
weight DNA was then precipitated and collected by a brief centrifugation of one min 
at 2000x g, 40C：. The DNA pellet was washed with two ml of 70% ethanol and dry by 
vacuum centrifuge for 10 mins. 
The desiccated DNA pellet was reconstituted in lOmM TRIS buffer, pH 8. After all, 
the quantity and quality of DNA was measured by the GeneQuant (Pharmacia, LKB 
Biochrom, England) spectrophotometer at the 260 and 280 nm wavelengths. 
3.3 Polymerase Chain Reaction (PCR) amplification of CTLA-4 gene 
exon one 
PCR amplification of CTLA-4 gene exon one was performed with primers forward 
5,-GCT CTA CTT CCT GAA GAC CT-3, and reverse 5,-AGT CTC ACT CAC CTT 
TGC AG-3, (Life Technologies, Rockville, Maryland, USA) according to the 
published human CTLA-4 complementary DNA sequence (Harper et al” 1991). In a 
10 ul PCR reaction, 70 ng genomic DNA, 200 uM dNTPs，Ix PCR buffer with 1.5 
mM Mg，2 pmol of each primer and 0.25U Taq DNA polymerase (Roche Diagnostics, 
Mannheim, Germany) were mixed and amplified in a thermocycler PTC-200 (MJ 
Research, Massachusetts, USA) under the following conditions: denaturation for two 
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minutes at 94^C, then cycled 30 times at 94°C for 30 sec.，58�C for 45 sec., and ITC 
for 30 sec., and finally with a extension step at 72®C for 2 mins (Dormer et al., 1997a). 
Successful amplification yields a 162 b.p. fragment. 
3.4 PGR Restriction Fragment Length Polymorphism (PCR-RFLP) 
analysis of CTLA-4 gene codon 17 A/G dimorphism 
The 162 bp CTLA-4 gene exon one PGR fragment was digested with restriction 
enzyme BZ>vI (New England Biolabs, Hertfordshire, England) as published previously 
(Dormer et al, 1997a). A 20 ul reaction containing 6 ul PCR product, Ix supplied 
restriction enzyme buffer and 0.5 U of Bbvl was incubated at 37®C overnight, 
followed by 3% agarose gel electrophoresis in Ix TAE buffer (40inM Tris acetate, 
2mM EDTA) at 10 V/cm for 20 mins. If a G nucleotide was present at position 49 of 
CTLA-4 gene codon 17，the enzyme would cut the 162 bp PCR product into two 
fragments of 88 bp and 74 bp respectively. No digestion would occur if an A 
nucleotide was present. The positions of PCR primers, BZ>vI restriction enzyme (RE) 
recognition site and RE cutting site were illustrated in Fig. 3.1. 
19 
Sense 5，TTTTGCTCTACTTCCTGAAGACCTGAACACCGCTCCCA 
Antisense 3' AAAACGAGATGAAGGACTTCTGGACTTGTGGCGAGGGT 
Sense 5，TAAAGCCATGGCTTGCCTTGGATTTCAGCGGCACAAGG 
Antisense 3’ ATTTCGGTACCGAACGGAACCTAAAGTCGCCGTGTTCC 
V * 
Sense 5’ CTCAGCTGAACCTGGCTGCCAGGACCTGGCCCTGCACT 
Antisense 3’ GAGTCGACTTGGACCGACGGTCCTGGACCGGGACGTGA 
A 
Sense 5, CTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAA 
Antisense 3’ GAGGACAAAAAAGAAGAGAAGTAGGGACAGAAGACGTT 
Sense 5' AGGTGAGTGAGACTTTTGGAG 
Antisense 3，TCCACTCACTCTGAAAACCTC 
Figure 3.1 The positions of PCR primers [underline], Bbvl restriction 
enzyme (RE) recognition site [bold] and RE cutting site 
[V A ] of the CTLA-4 gene exon 1. The [ * ] indicated the 
position of the A/G nucleotide polymorphism. 
20 
3.5 PGR Single Strand Conformation Polymorphism (PCR-SSCP) 
analysis of CTLA-4 gene codon 17 A/G dimorphism 
3.5.1 Preparation of SSCP gel and buffer 
PCR-SSCP analysis was carried out as described (Donner et aL, 1997a) with slight 
modifications (Orita et al., 1989). SSCP polyacrylamide gel solution was prepared by 
mixing 20 ml of 40 % polyacrylamide stock solution (39 gm acrylamide and 1 gm 
bis-acrylamide in 100 ml distilled water), 5 ml of lOx TBE (890 mM TRIS, 890 mM 
Boric Add，20mM EDTA), 2 ml of 50 % glycerol (v/v), 100 mg of Ammonium 
Persulphate, 65 ul of TEMED and 73 ml of distilled water. The SSCP gel was casted 
on a vertical sequencing apparatus (Model S2，GIBCO BRL, Life Technologies, USA) 
with 48 well shark-tooth comb. Then the SSCP gel and SSCP running buffer (0.5x 
TBE, 1% glycerol) was chilled at 4 before use. 
3.5.2 5' end labelling of forward PCR primer 
The forward primer was 5，end labelled with Redivue [y-^ ^p] ATP (10 uCi/ul) 
(Amersham Pharmacia Biotech, Buckinghamshire, England) using T4 polynucleotide 
kinase (T4 PNK) (Life Technologies, Rockville, Maryland, USA). In a 25 ul reaction 
volume, 5 pmol each of forward primer and Redivue [y-^ ^p] ATP were mixed with Ix 
forward reaction buffer (supplied with T4 PNK) and 10 units of T4 PNK. Labelling 
reaction was carried out by incubation at 37 for 10 mins followed by a heat 
inactivation step at 65 ®C for 10 mins. 
3.5.3 Preparation of PCR fragment for SSCP analysis 
Forward labelled primer were substituted for the non-labelled primer in CTLA-4 gene 
exon one PCR as described above. One ul of PCR product was mixed with 9 ul of 
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denaturing buffer (95% formamide, 0.05% bromophenol blue, 0.05% xylene cyanol) 
and the mixture was heated at 95 for 5 mins followed by quenching 15 mins on ice 
before loading to the SSCP polyacrylamide gel. 
3.5.4 SSCP analysis 
The chilled SSCP gel was pre-run at a constant current of 10mA for 5 mins at 4®C to 
ensure the gel is current conducting and leakage free. Then two ul of denatured PGR 
fragment was loaded on each sample lane. The gel was run at a constant current of 
10mA for 2 hours at 4°C. 
3.5.5 Autoradiography 
The SSCP gel was backup by blotting on Whatman 3MM chromatography paper 
(Whatman, USA)，and covered by Saran-wrap. Then the gel was thoroughly dried 
using a gel dryer (Model 583, BioRad, USA). An X-ray film (X-OMAT AR, Kodak, 
Roshester, USA) placed on top of the Saran-wrap together with dry gel was placed 
inside a film cassette containing intensifying screen (Okamato, Tokyo, Japan), scissor 
cuttings were made on the film and gel to mark the orientation. The film was exposed 
for 4 hours to overnight at room temperature and developed by an automatic X-ray 
film processor (Model Okamoto X3, Tokyo, Japan). 
3.6 Sequence confirmation of the SSCP fragment by PGR cycle sequencing 
3.6.1 Preparation of sequencing template from SSCP fragment 
The fragment on the SSCP dry gel was located by pins, which pierced through the 
developed X-ray film superimposed on the dry gel. Then the desired fragment was 
cut out and re-hydrated overnight in 100 ul deionized distilled water at One ul of 
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the aqueous phase from the gel re-hydrate mixture was used as template to PGR re-
amplified the CTLA-4 gene exon one as described above. The re-amplified PGR 
product was analysed on 1% agarose gel and then extracted using the Sephaglas 
BandPrep Kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to 
manufacturer instructions. 
3.6.2 PGR cycle sequencing 
Cycle sequencing was performed using the BigDye Terminator Cycle Sequencing Kit, 
VI.1 (Applied Biosystems, Foster City, California, USA). A 20 ul reaction which 
contains 30 ng of Sephaglas BandPrep Kit purified PGR product, 3.2 pmol of forward 
primer and 8 ul of Terminator Ready Reaction Mix were subjected to thermal cycling 
in thermocycler PTC-200 (MJ Research, Massachusetts, USA) under the following 
conditions: cycled 25 times at 96°C for 10 sec., 50°C for 5 sec., and 60°C for 2 mins. 
3.6.3 Preparation of cycle sequencing products for electrophoresis 
Ethanol precipitation was used to remove excess dye terminators. PCR cycle 
sequencing product was added with one-tenth volume of sodium acetate (3M, pH 4.6), 
followed by a two volume of absolute ethanol and the mixture was placed at —20�C 
for 10 mins. The precipitate was pelleted by bench top centrifiigation at 18000x g for 
30 mins. Then the pellet was washed with 250 ul of 70% ethanol and dry for 10 mins 
in a vacuum centrifuge. Finally, the pellet was resuspended in 12 ul of Template 
Suppression Reagent (TSR) (Applied Biosystems, Foster City, California, USA), 
denature at 95®C for 2 mins and then chill on ice before electrophoresis. 
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3.6.4 Sequencing by capillary electrophoresis (CE) 
Sequencing analysis was performed by CE on the ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems, Foster City, California, USA). Briefly, the valve block and the 
capillary was setup in good alignment and leakage free conditions according to 
instrument manual. Polymer pop-6 (Applied Biosystems, Foster City, California, 
USA) and short capillary (47cm) was used for sequencing. The denatured sample in 
TSR was loaded onto the sample tray and run at 15 KV for 25 mins with sample 
injection time adjusted between 15 to 30 seconds. 
3.7 Statistical analysis 
The X -test will be used for the statistical comparison between Graves' disease group 
and the control group with respect to: 
(1) Genotype frequencies, i.e., the proportion of a population that has one 
genotype relative to all genotypes (AA, AG and GG) at the CTLA-4 gene 
codon 17 dimorphism locus. 
(2) Allele frequencies, i.e., the proportion of one allele relative to all alleles at the 
CTLA-4 gene codon 17 dimorphism locus in the population. 
(3) Phenotype frequencies, i.e., the proportion of a population that has one 
phenotype relative to all phenotypes at the CTLA-4 gene codon 17 
dimorphism locus. 
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The odds ratio (OR) was calculated using the statistical programme Epi Info 6， 




Results and Data Analysis 
4.1 Results 
4.1.1 Demographic data of case and control subjects 
There are a total of 123 (104 girls and 19 boys) unrelated Chinese children with 
Graves' disease were recruited. The mean age of the patients at presentation (mean 
age 土 S.D.) was 11.6 土 2.8 years and their ages ranged from 2.7 to 14.9 years. The 
158 (79 girls and 79 boys) age-matched controls were all less than 15 years old. The 
mean age of the controls was 11.8 土 2.5 years. 
4.1.2 PGR amplification of CTLA-4 gene exon one 
The CTLA-4 gene exon one was successfully PCR amplified. 1% agarose gel 
electrophoresis indicated the presence of the predicted 162 b.p. fragment. The 
agarose gel photo was illustrated in fig. 4.1. 
4.1.3 PCR-RFLP analysis of CTLA-4 gene codon 17 A/G dimorphism locus 
The CTLA-4 gene exon one PCR fragment was cleaved by the RE BZ)vI. Three 
restriction fragment patterns were observed upon 3% agarose gel electrophoresis. 
Homozygous AA fragment remains intact at 162 b.p. while the homozygous GG 
fragment was cleaved to two fragments of 88 b.p. and 74 b.p. Heterozygous AG 
subjects have both patterns conserved. A representative photo of CTLA-4 exon one 
PCR-RFLP cutting by BM was illustrated in fig. 4.2. 
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Figure 4.2 
Agarose (3%) gel electrophoresis of the 162 b.p. CTLA-4 gene exon 1 
PCR fragment cleaved by the restriction enzyme Bivl . 
Subjects: (1) and (2)，homozygous AA 
(5) and (6), homozygous GG 
(3) and (4)，heterozygous AG 
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4.1.4 PCR-SSCP analysis of CTLA-4 gene codon 17 A/G dimorphism locus 
PCR-SSCP analysis clearly demonstrated three types of fragment migration patterns. 
The single strand “A，，fragment was migrated faster relative to the single strand "G" 
fragment. Homozygous AA or GG subjects were shown to have only either "A" or 
"G" fragment respectively. Heterozygous AG subjects have both fragments. A 
typical PCR-SSCP pattern of selected samples was shown in fig. 4.3. The actual 40 
lanes PCR-SSCP sample analysis pattern was shown in fig. 4.4. 
(1) (2) (3) (4) (5) (6) 
1 1 ' 二 _ _ fcii _ ^ r ^ A > wm mm _ _ _ • 
Figure 4.3 
PCR-SSCP analysis of the CTLA-4 gene exon 1 fragment at 
A and G denotes the position of single strand “A，, and “G’， 
fragment respectively. Subjects (1) and (2)，homozygous AA; (5) and (6)， 
homozygous GG; (3) and (4)，heterozygous AG 
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Figure 4.4 
40 lanes PCR-SSCP analysis of the CTLA-4 gene exon 1 fragment at 
"A" and "G" indicated the position of single strand A and G fragment 
respectively. 
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4.1.5 PGR cycle sequencing of the SSCP fragments 
Cycle sequencing of the SSCP fragment confirmed the faster and slower migrating 
fragment at 4°C contains the nucleotide “A” and “G” respectively at the CTLA-4 gene 
exon one codon 17 (position 49) A/G dimorphism locus. The electrophoerogram 
showing the sequence of SSCP fragment was provided in fig. 4.5. 
(A) Fast migrating SSCP “A” fragment (B) Slow migrating SSCP “G” fragment 
C C T G G C T j ^ C CAGG ACCT G( C CT GG C T ^ CAG G AC C T G( 
n _ : � 1 1 丨 】 I � I 
iMUJM iiiMi 
Figure 4.5 
Sequencing analysis of the PCR-SSCP fragment. 
The position of A/G nucleotide dimorphism was underlined. 
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4.2 Data analysis 
4.2.1 Overview of data 
Using our SSCP and PCR product restriction fragment length approaches，the CTLA-
4 exon 1 polymorphism was unambiguously assigned in 123 patients with Graves' 
disease and 158 controls. The distribution of CTLA-4 alleles in all studied groups 
was in Hardy-Weinberg equilibrium. 
4.2.2 CTLA-4 exon one polymorphism analysed with respect to sex 
As CTLA-4 association with Graves，disease may differ according to sex, the 
association was analysed according to sex (Table 4.1). The distributions of genotype 
and allele frequencies differed between female patients and controls (% =9.58， 
P=0.008; and P=0.033, respectively). In female subjects, the odds ratio 
conferred by the G phenotype (GG or AG) for the development of Graves' disease 
was 5.7 (95% CI = 1.7-30.5，P=0.002). The G phenotype and G allele tended to be 
more frequent in the male patients when compared with the controls, but the 
differences in the distributions of genotypes and allele frequencies did not reach 
statistical significance. 
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Table 4.1 CTLA-4 exon one polymorphism analysed with respect to sex 
Male patients Female patients Controls 
n=19 n=104 n=158 
Genotype frequencies 
GG 10 (52.6 %) 56 (53.8%)* 76 (48.1 %) 
AG 9 (47.4 %) 45 (43.3 %) 59 (37.3 %) 
AA 0(0%) 3(2.90/0) 23 (14.6 %) 
Allele frequencies 
G 29 (76.3%) 157 (75.5%)** 211 (66.8%) 
A 9 (23.7%) 51 (24.5%) 105 (33.2 %) 
Phenotype frequencies 
G positive 19 (100%) 101 (97.1%)*** 135 (85.4%) 
A positive 9 (47.4%) 48 (46.2%) 82 (51.9%) 
Values given are the number of subjects, with the percentage in parentheses. 
* P = 0.008, y^ - 9.58 (female patients compared with controls). 
** P-0.033，X = 4.55 (female patients compared with controls). 
**• Odds ratio for G phenotype in female patients = 5.7 (95% CI = 1.7-30.5)，P = 
0.002. 
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4.2.3 CTLA-4 exon one polymorphism in patients with Graves' disease and controls 
Since the distribution of the genotype frequencies of the CTLA-4 alleles did not differ 
between male and female controls, the data were combined and used for statistical 
analysis in comparing with patients. Table 4.2 shows the distribution of CTLA-4 
exon 1 polymorphism in patients and control subjects. The genotype frequencies 
differed significantly between patients and controls (x^=12.14, P=0.0023). The 
distribution of allele frequencies also differed significant between patients and 
controls (x^=5.21, P=0.022). The presence of at least one G allele (GG or AG) 
conferred an odds ratio of 6.8 (95% CI = 2.0-36.1, P=0.001) for the development of 
Graves' disease. 
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Table 4.2 CTLA-4 exon 1 polymorphism in patients with Graves' disease and 
controls 




GG 66 (53.7%) 76 (48.1 %) 
AG 54(43.9%) 59 (37.3 %) 
AA 3 (2.4 %) 23 (14.6 %) 
Allele frequencies** 
G 186 (75.6 %) 211 (66.8%) 
A 60 (24.4%) 105 (33.2%) 
Phenotype frequencies 
G positive*** 120 (97.6%) 135 (85.4%) 
A positive 57 (46.3%) 82 (51.9%) 
Values given are the number of subjects, with the percentage given in parentheses. 
* P = 0.0023，x2= 12.14. 
** P = 0.022，乂2 = 5.21. 




Graves' disease is a common autoimmune thyroid disorder characterized by the 
development of thyrotropin-receptor antibodies and TSH receptor antibody 
production is regulated by TSHR-specific T cells (Okamoto et “/•，1994). As 
childhood Graves' disease has been found to be common in Chinese children, it 
would be important to identify the possible environmental and genetic factors which 
predispose the Chinese children to develop the disease. All of the genes involved in 
antigen-specific T-cell activation are possible candidate genes for susceptibility to 
Graves' disease. Co-stimulation has been found to be important in regulating self-
tolerance mediated by the interaction of CD28/CTLA-4 molecules on T cells and B7 
molecules on antigen-presenting cells. Many recent studies, therefore, have been 
performed evaluating the role of the CTLA-4 gene in the development of various 
autoimmune diseases, such as Graves' disease, Hashimoto's thyroiditis, diabetes 
mellitus, Addison's disease and coeliac disease (Chistiakov and Turakulov, 2003). 
The first study demonstrating an association between a microsatellite polymorphism 
of the CTLA-4 gene (allele 106 bp) and Graves' diseases was performed in 
Caucasians adults (Yanagawa et al； 1995). Subsequently the association between the 
CTLA-4 exon 1 A/G transition polymorphism and Graves' disease has been found in 
various adult populations (Donner et al, 1997a; Yanagawa et al., 1997). In 
Caucasian and Japanese adults, the G phenotype conferred an odds ratio of 2.0 and 
2.6 for the development of Graves' disease. Increased transmission of the G allele 
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from heterozygous parents to affected offspring compared to unaffected offspring has 
also been confirmed in a recent linkage study in Caucasians (Heward et al, 1999). 
However, ophthalmopathy in adult patients with Graves' disease appeared not to be 
associated with the CTLA-4 gene (Allahabadia et al.，2001). 
This is the first study to investigate the association of CTLA-4 gene A-G 
polymorphism and childhood Graves' disease. Although childhood Graves' disease is 
rare in Caucasian populations, the incidence of this disease is very high in Hong Kong 
Chinese children. Therefore, we were able to study a relatively large group of 
children with Graves' disease. For genetic association studies, there may be an 
advantage to study children than adults because the genetic contribution may be less 
likely to be diluted by the effect of environmental factors in the manifestation of the 
disease in children. Our results confirmed that the presence of at least one G allele 
(GG or AG) confers susceptibility to Graves' disease in Chinese children. The odds 
ratio conferred by the G phenotype in children (6.8) was higher than those reported in 
adults (Donner et aL, 1997a; Yanagawa et al.’ 1997). This may not be surprising 
because the genetic predisposition may be stronger in children than in adults when the 
disease manifests early in childhood. A comparison of genetic association studies 
carried out in both children and adults may further elucidate other environmental 
factors other than genetics in the pathogenesis of GD. Lower odds ratio of disease 
susceptibility genes in adult may imply that the effect of genes was diminished 
throughout years of disease development because of “gene to gene" or "environment 
to gene" interactions. Studies using immigrants of the same population is an 
alternative to investigate the effect of environment on disease prone genotypes. 
37 
Upon the completion of this study, there is the identification of new single nucleotide 
polymorphisms (SNPs) in the CTLA-4 gene and the association of sCTLA-4 isoform 
expression. A 300 Kb region of chromosome 2q33 containing CD28, CTLA-4 and 
ICOS genes was sequenced (Ueda et al., 2003). A total of 108 SNPs and the CTLA-4 
(AT)n - 3，untranslated region (UTR) marker were genotyped in 384 cases of GD and 
652 controls to determine their allele frequencies. By this fine mapping of the CTLA-
4 gene, the susceptibility locus was located to a 6.1 Kb region 3' of the CTLA-4 gene, 
containing four SNPs designated CT60, JOOl, J030 and J027一 1. The marker CT60 
(OR = 1.51，95% CI = 1.31-1.75; P = 2.72 x 10-8) was the most-associated with GD 
(Ueda et al., 2003). The association of this CT60 marker with GD was also found 
later in the Italian (Petrone et aL, 2005), Japanese (Ban Y et al., 2005) and Taiwanese 
(Weng et al., 2005) population with OR ranged from 1.8-2.0 for the disease 
susceptible CT60 G allele. 
Unstimulated CD4 T cells from 14 healthy subjects with various CT60 genotypes 
(four A/A, six A/G, four G/G) were assayed for the sCTLA-4 transcript level relative 
to the full-length CTLA-4 transcript. It was found that the expression level of 
sCTLA-4 is A/A > A/G > G/G (Ueda et al, 2003). The disease susceptible G/G 
genotype has fewer sCTLA-4 transcripts. Recent reviews (Fountoulakis et al., 2004 
and Vaidya B et al., 2004) on the pathogenesis of autoimmune thyroid disease (AITD) 
speculate these findings with an earlier investigation that elevated plasma levels of 
sCTLA-4 protein were more frequent in AITD patients (11 out of 20) than in healthy 
controls (1 out of 30) (Oaks and Hallett, 2000). 
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This phenomenon may be explained by the fact that the above two studies are looking 
at different subjects at different disease stages. Normally, sCTLA was expressed in 
non-activated T cells and rapidly down regulated upon T cell activation. Healthy 
subjects with disease protective genotype (CTLA-4 gene CT60 A/A) investigated by 
Ueda et al. has more sCTLA-4, this may increase blocking of the B7 molecules, 
causing opposed T cell activation through competition with CD28 and establish a 
threshold for T cell activation. Oaks and Hallett et al studying subjects that already 
have AITD. In contrast to the healthy state, sCTLA-4 cannot be down regulated. 
Increased sCTLA-4 may compete with the membrane-bound CTLA-4 for B7 binding, 
so that the membrane- bound CTLA-4 molecules cannot appropriately provide 
inhibitory signal to the activated T cells. 
Modulation of the gene splicing pattern can led to the regulation of protein function 
and may even modify disease severity (Nissim-Rafinia and Kerem, 2005). Indeed, 
candidate genes confer susceptibility to diseases such as autoimmune diseases (Ueda 
et al,, 2003), Alzheimer's (Bertram et al” 2005) and asthma (Laitinen et al.，2004) 
were found to produce alternatively spliced isoforms of specific genes, the ratio of 
which varies between normal and affected individuals. Understanding of the CTLA-4 
gene transcriptome in the future may provide a clue to the pathogenesis of 
autoimmune diseases. 
Besides the competitive antagonism of CD28 signals and direct negative signalling 
mechanisms of T cell inhibition, CTLA-4 may also modulate immune response via 
other pathways (Gough et al., 2005). CTLA-4 has a role in T regulatory cell 
activation and proliferation (Tang et a/” 2003 and Zheng et al., 2004), it can up 
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regulate the enzyme indoleamine 2,3-dioxygenase (IDO) which breakdown the amino 
acid tryptophan and inhibits T-cell activation (Grohmaim et a!” 2002), it also affects 
T helper cell differentiation (Walunas et al.’ 1998 and Oosterwegel et al； 1999) and 
involved in protein trafficking within the immunological synapse (Darlington et al., 
2002). 
Several recent studies have also demonstrated the association of CTLA-4 gene and 
type 1 diabetes mellitus in Caucasians (Nistico et al,, 1996; Marron et al.，1997). 
Transmission study has also revealed preferential transmission of the CTLA-4 exon 1 
G allele to affected offspring in Italians and Spanish but not in Koreans and Chinese 
(Marron et al.’ 1997). A recent study of a larger group of Chinese children with type 
1 diabetes, however, demonstrated that the G allele conferred a risk of 2.13 (Lee et al., 
2000). A case-control study of Japanese diabetic patients, however, failed to show 
any association of the allele G with the disease (Yanagawa et al.’ 1999). Failure to 
show the association may also be due to possible dilution of the CTLA-4 associated 
susceptibility by other genetic factors, which may have a greater effect than CTLA-4 
and are only present in certain ethnic groups. Although the CTLA-4 gene has also 
been shown to be associated with other autoimmune diseases such as Hashimoto's 
thyroiditis, Addison's disease and rheumatoid arthritis (Kotsa et a!., 1997; Donner et 
al., 1997b; Kemp et al.,1998; Seidl et al., 1998)，the association of the CTLA-gene 
with Graves' disease appears to be the strongest among the various conditions studied 
as indicated by higher odds ratio. In addition, one study in Caucasians demonstrated 
that the GG genotype was associated with more severe biochemical disease at 
presentation (Heward et al., 1999). Recently Tomer et ai reported a linkage study 
suggesting that CTLA-4 gene might contribute to the genetic susceptibility of thyroid 
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antibody production (Tomer et al； 2001). Our study provides further evidence to 
support the important role of the CTLA-4 gene in the development of childhood 
Graves' disease. 
In order to determine any possible sex difference in the association of Graves' disease 
with the CTLA-4 gene, we compared the frequencies of the two alleles in male and 
female patients separately with the controls. In female subjects, the odds ratio 
conferred by the G phenotype was 5.7 for the development of Graves' disease. 
Although the G phenotype and G allele were more frequent in the male patients than 
in controls, the differences did not reach statistical significance probably related to the 
small sample size. Further studies involving more male patients are required to reveal 
the possible sex difference in the association of CTLA-4 gene and childhood Graves' 
disease. 
The result of the present study confirms that CTLA-4 G allele at position 49 of exon 1 
is associated with Graves' disease in Chinese children. It is unlikely that this A/G 
polymorphism is the candidate gene because the Thr/Ala substitution is not expected 
to have any significant functional consequences. Further studies are necessary to 
clarify the exact mechanism of this CTLA-4 gene polymorphism resulting in 
increased susceptibility to Graves' disease and other autoimmune diseases. 
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Chapter 6 
Summary and Conclusions 
Graves，disease is one of the most common organ-specific autoimmune endocrine 
conditions. Although this condition has been found to be relatively rare in children, 
the incidence of childhood Graves' disease has been found to be very high in Chinese 
children from Hong Kong (Wong et al., 2001). There have been many recent studies 
directing at revealing the possible genetic predisposition of Graves' disease. The 
majority of studies focused on the genes that are important for the regulation of 
immune responses (Simmonds and Gough, 2004). Another main focus of research in 
recent years is the relationship of CTLA-4 gene and autoimmune diseases. The B7-
CTLA-4 co-stimulatory pathway has been found to be important in the pathogenesis 
of many autoimmune diseases including Graves' disease, diabetes mellitus, celiac 
disease and Addison's disease (Reiser and Stadecker, 1996; Vaidya and Pearce, 2004). 
The association of the CTLA-4 gene and Graves，disease was first reported in 
Caucasians (Yanagawa et al., 1995). The subsequent discovery of the CTLA-4 A/G 
polymorphism facilitates many other studies of CTLA-4 gene and Graves' disease 
(Chapter 2). The G allele has consistently been found to confer increased risk of 
developing Graves' disease. 
As childhood Graves' disease has been found to be quite common in Hong Kong, 
research studies of the possible environmental or genetic factors predisposing to the 
development of Graves' disease in Hong Kong are important. Previous study of the 
HLA genes in Chinese children suggested that there are race-specific HLA-DQ alleles 
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conferring susceptibility or protection for Graves' disease (Wong et al” 1999). The 
current thesis attempted to study the association of CTLA-4 gene and childhood 
Graves' disease in Chinese. A total of 123 patients and 158 racially matched controls 
were successfully recruited and studied. The CTLA-4 A/G polymorphism was 
successfully typed in all subjects. We confirmed that strong association of the G 
allele and GG genotype and Graves' disease in Chinese children. Comparing to 
Caucasian and Japanese data available in the literature, the G allele was found to be 
relatively more common in the Chinese population. The higher frequency of the G 
allele in Chinese may contribute to the higher incidence of Graves' disease in Chinese 
children. 
The number of male subjects with Graves' disease is relatively small in our study. In 
order to confirm such association in male subjects, a larger number of male patients is 
needed and we are collecting these cases on a continuing basis. Furthermore, 
additional studies of adult patients as well as patients from other parts of China are 
needed. Childhood Graves' disease has been reported to be rather uncommon in 
Mainland China (Qingdao Goiter Study Group, 1991) but there has not been any 
population based epidemiological study of childhood Graves' disease in Mainland 
China. There is also a possibility that some other unknown environmental factors 
may also be important in contributing to the high incidence of childhood Graves， 
disease in Hong Kong. Further studies of other genetic markers as well as 
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